PSP Research
Latest statistics and disclosures from PSP Research's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, SGOV, RPRX, NRIX, INCY, and represent 86.49% of PSP Research's stock portfolio.
- Added to shares of these 10 stocks: XBI (+$45M), Ascendis Pharma AS, LQDA, KRYS, AVBP, JAZZ, RVMD, RYTM, DNLI, ARWR.
- Started 11 new stock positions in SRRK, LQDA, Ascendis Pharma AS, KRYS, CTMX, AVBP, JAZZ, DNLI, ARWR, RYTM. RVMD.
- Reduced shares in these 10 stocks: SERA, DFTX, CMPS, TYRA, ASND, CYTK, AGIO, PRAX, INBX, AXSM.
- Sold out of its positions in AGIO, APGE, ASND, CELC, CMPX, CYTK, ERAS, INBX, KALV, LEGN. PRAX, SERA, SMMT, TYRA, UTHR.
- PSP Research was a net buyer of stock by $31M.
- PSP Research has $188M in assets under management (AUM), dropping by 32.94%.
- Central Index Key (CIK): 0002106939
Tip: Access up to 7 years of quarterly data
Positions held by PSP Research consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for PSP Research
PSP Research holds 75 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr Series Trust St Str Sp Biot (XBI) | 48.0 | $90M | +100% | 570k | 158.25 |
|
| Ishares Tr 0-3 Mth Treasury (SGOV) | 37.5 | $71M | 700k | 100.67 |
|
|
| Royalty Pharma Shs Class A (RPRX) | 0.3 | $617k | 11k | 56.07 |
|
|
| Nurix Therapeutics (NRIX) | 0.3 | $607k | -12% | 25k | 24.26 |
|
| Incyte Corporation (INCY) | 0.3 | $601k | 5.3k | 113.36 |
|
|
| Argenx Se Sponsored Adr (ARGX) | 0.3 | $595k | 641.00 | 927.77 |
|
|
| Disc Medicine (IRON) | 0.3 | $585k | 8.0k | 73.14 |
|
|
| Rapport Therapeutics (RAPP) | 0.3 | $583k | 14k | 41.67 |
|
|
| Ultragenyx Pharmaceutical (RARE) | 0.3 | $568k | -23% | 17k | 33.39 |
|
| Trevi Therapeutics (TRVI) | 0.3 | $560k | 30k | 18.65 |
|
|
| Monte Rosa Therapeutics (GLUE) | 0.3 | $557k | -17% | 23k | 24.20 |
|
| Tg Therapeutics (TGTX) | 0.3 | $549k | -23% | 10k | 54.94 |
|
| Halozyme Therapeutics (HALO) | 0.3 | $548k | -12% | 7.0k | 78.27 |
|
| Ionis Pharmaceuticals (IONS) | 0.3 | $539k | 6.8k | 79.29 |
|
|
| Pharvaris N V (PHVS) | 0.3 | $519k | -25% | 15k | 34.58 |
|
| Arcutis Biotherapeutics (ARQT) | 0.3 | $517k | 20k | 26.22 |
|
|
| Aurinia Pharmaceuticals (AUPH) | 0.3 | $509k | 30k | 16.97 |
|
|
| Neurocrine Biosciences (NBIX) | 0.3 | $506k | -22% | 3.0k | 168.53 |
|
| Immunovant (IMVT) | 0.3 | $501k | -32% | 13k | 38.53 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.3 | $500k | 20k | 25.30 |
|
|
| Ptc Therapeutics I (PTCT) | 0.3 | $489k | 6.0k | 81.57 |
|
|
| Celldex Therapeutics Com New (CLDX) | 0.3 | $484k | 13k | 37.21 |
|
|
| Immunocore Hldgs Ads (IMCR) | 0.3 | $481k | 15k | 31.75 |
|
|
| Definium Therapeutics Com Shs (DFTX) | 0.3 | $470k | -71% | 10k | 47.04 |
|
| Cogent Biosciences (COGT) | 0.2 | $464k | 12k | 38.70 |
|
|
| Kymera Therapeutics (KYMR) | 0.2 | $459k | -36% | 4.0k | 114.67 |
|
| Dyne Therapeutics (DYN) | 0.2 | $444k | 20k | 22.21 |
|
|
| Alnylam Pharmaceuticals (ALNY) | 0.2 | $441k | 1.5k | 301.03 |
|
|
| Tarsus Pharmaceuticals (TARS) | 0.2 | $441k | 7.0k | 62.94 |
|
|
| Syndax Pharmaceuticals (SNDX) | 0.2 | $437k | 20k | 21.86 |
|
|
| Exelixis (EXEL) | 0.2 | $435k | -33% | 8.0k | 54.41 |
|
| Crinetics Pharmaceuticals In (CRNX) | 0.2 | $412k | 11k | 37.42 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.2 | $407k | -20% | 12k | 33.89 |
|
| Ascendis Pharma A/s Ord Shs | 0.2 | $400k | NEW | 1.5k | 266.72 |
|
| Liquidia Corporation Com New (LQDA) | 0.2 | $399k | NEW | 5.0k | 79.73 |
|
| Stoke Therapeutics (STOK) | 0.2 | $393k | 12k | 32.72 |
|
|
| Viking Therapeutics (VKTX) | 0.2 | $390k | -33% | 10k | 39.01 |
|
| Immunome (IMNM) | 0.2 | $381k | -10% | 18k | 21.19 |
|
| Protagonist Therapeutics (PTGX) | 0.2 | $368k | 3.0k | 122.58 |
|
|
| Harmony Biosciences Hldgs In (HRMY) | 0.2 | $364k | -29% | 10k | 36.41 |
|
| Enliven Therapeutics (ELVN) | 0.2 | $355k | 7.0k | 50.75 |
|
|
| Spyre Therapeutics Com New (SYRE) | 0.2 | $355k | -22% | 4.0k | 88.78 |
|
| Intellia Therapeutics (NTLA) | 0.2 | $338k | -25% | 20k | 16.92 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.2 | $322k | 600.00 | 536.95 |
|
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 0.2 | $320k | -44% | 5.0k | 63.95 |
|
| Alkermes SHS (ALKS) | 0.2 | $314k | 6.0k | 52.40 |
|
|
| Tango Therapeutics (TNGX) | 0.2 | $313k | -30% | 10k | 31.26 |
|
| Ardelyx (ARDX) | 0.2 | $306k | -25% | 60k | 5.10 |
|
| Vera Therapeutics Cl A (VERA) | 0.2 | $300k | -30% | 7.0k | 42.91 |
|
| Mirum Pharmaceuticals (MIRM) | 0.2 | $293k | -50% | 2.5k | 117.07 |
|
| Oruka Therapeutics (ORKA) | 0.2 | $286k | -39% | 3.0k | 95.17 |
|
| Supernus Pharmaceuticals (SUPN) | 0.1 | $279k | 6.0k | 46.51 |
|
|
| Crispr Therapeutics Namen Akt (CRSP) | 0.1 | $273k | -47% | 5.0k | 54.54 |
|
| Zymeworks Del (ZYME) | 0.1 | $261k | 10k | 26.14 |
|
|
| Krystal Biotech (KRYS) | 0.1 | $257k | NEW | 692.00 | 371.67 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.1 | $255k | -74% | 18k | 14.15 |
|
| Xenon Pharmaceuticals (XENE) | 0.1 | $254k | 4.2k | 60.36 |
|
|
| Axsome Therapeutics (AXSM) | 0.1 | $245k | -64% | 1.0k | 244.77 |
|
| Arrivent Biopharma (AVBP) | 0.1 | $245k | NEW | 7.0k | 34.74 |
|
| Dianthus Therapeutics (DNTH) | 0.1 | $244k | -50% | 2.5k | 97.48 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 0.1 | $234k | NEW | 971.00 | 240.97 |
|
| Kodiak Sciences (KOD) | 0.1 | $234k | -40% | 6.0k | 38.96 |
|
| Revolution Medicines (RVMD) | 0.1 | $225k | NEW | 1.2k | 187.28 |
|
| Bridgebio Pharma (BBIO) | 0.1 | $223k | -50% | 3.0k | 74.48 |
|
| Rhythm Pharmaceuticals (RYTM) | 0.1 | $222k | NEW | 2.0k | 111.03 |
|
| Denali Therapeutics (DNLI) | 0.1 | $218k | NEW | 8.5k | 25.72 |
|
| Arrowhead Pharmaceuticals (ARWR) | 0.1 | $212k | NEW | 2.6k | 81.51 |
|
| Scholar Rock Hldg Corp (SRRK) | 0.1 | $211k | NEW | 3.8k | 55.00 |
|
| Edgewise Therapeutics (EWTX) | 0.1 | $203k | -23% | 5.0k | 40.63 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.1 | $195k | 11k | 17.96 |
|
|
| Cytomx Therapeutics (CTMX) | 0.1 | $148k | NEW | 39k | 3.75 |
|
| Ocular Therapeutix (OCUL) | 0.1 | $147k | 15k | 9.82 |
|
|
| Eyepoint Com New (EYPT) | 0.1 | $143k | 10k | 14.30 |
|
|
| Oric Pharmaceuticals (ORIC) | 0.1 | $141k | 13k | 10.83 |
|
|
| Olema Pharmaceuticals (OLMA) | 0.1 | $125k | 10k | 12.51 |
|
Past Filings by PSP Research
SEC 13F filings are viewable for PSP Research going back to 2025
- PSP Research 2026 Q2 filed July 9, 2026
- PSP Research 2026 Q1 filed April 17, 2026
- PSP Research 2025 Q4 filed Feb. 6, 2026